Poll

POLL: Will you use biosimilars in your ophthalmic practice?

Author(s):

Sheryl Stevenson

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Will you use biosimilars in your ophthalmic practice?

Yes, I plan to use biosimilars in my practice
No, I do not plan to use biosimilars in my practice

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
Related Content
(Image credit: AdobeStock/upnowgraphics) Ophthalmology Times: AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium
June 9th 2025

AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/zinkevych) FDA nod for acoltremon: What its approval means for clinicians and patients
June 7th 2025

FDA nod for acoltremon: What its approval means for clinicians and patients

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801
June 5th 2025

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801

Ocugen signs term sheet for korean licensing of OCU400 gene therapy
June 5th 2025

Ocugen signs term sheet for korean licensing of OCU400 gene therapy

© 2025 MJH Life Sciences

All rights reserved.